

## CLAIMS

What is claimed is:

1. A method of treating hormonal deficiencies in a woman undergoing estrogen replacement therapy, the method comprising administering to said woman, continuously and uninterruptedly, a therapeutic effective amount of both estrogen and a non-aromatizing androgen in daily dosages.
2. The method of Claim 1, wherein the estrogenic compound is selected from the group consisting of estrone, 17 $\alpha$ -estradiol, 17 $\beta$ -estradiol, equilin, 17 $\alpha$ -dihydroequilin, 17 $\beta$ -dihydroequilin, equilenin, 17 $\alpha$ -dihydroequilenin, 17 $\beta$ -dihydroequilenin,  $\Delta^{8,9}$ -dehydroestrone, 17 $\alpha$ - $\Delta^{8,9}$ -dehydroestradiol, 17 $\beta$ - $\Delta^{8,9}$ -dehydroestradiol, ethinyl estradiol, estradiol valerate, 6-OH equilenin, 6-OH 17 $\alpha$ -dihydroequilenin, 6-OH 17 $\beta$ -dihydroequilenin, and mixtures, conjugates and salts thereof.
3. The method of Claim 1, wherein the non-aromatizing androgenic compound is selected from the group consisting of oxandrolone, oxymetholone, stanozolol, danazol, pharmaceutically acceptable esters and salts thereof, and combinations of any of the foregoing.
4. The method of Claim 1, further comprising administering a progestin in a daily dose.
5. A method of treating hormonal deficiencies in a woman undergoing estrogen replacement therapy, the method comprising administering to said woman, continuously and uninterruptedly, a therapeutically effective amount of both estrogen and androgen in daily dosages of an estrogenic compound equivalent to oral estradiol dosages of about 0.1 to 3 mg, and of a non-aromatizing androgenic compound equivalent to oral dosages of about 0.1 to 10 mg.
6. The method of Claim 5, wherein the estrogenic compound is selected from the group consisting of estrone, 17 $\alpha$ -estradiol, 17 $\beta$ -estradiol, equilin, estriol, 17 $\alpha$ -dihydroequilin, 17 $\beta$ -dihydroequilin, equilenin, 17 $\alpha$ -dihydroequilenin, 17 $\beta$ -dihydroequilenin,  $\Delta^{8,9}$ -dehydroestrone, 17 $\alpha$ - $\Delta^{8,9}$ -dehydroestradiol, 17 $\beta$ - $\Delta^{8,9}$ -dehydroestradiol, ethinyl estradiol, estradiol valerate, 6-

OH equilenin, 6-OH 17 $\alpha$ -dihydroequilenin, 6-OH 17 $\beta$ -dihydroequilenin, and mixtures conjugates and salts thereof.

7. The method of Claim 5, wherein the non-aromatizing androgenic compound is selected from the group consisting of oxandrolone, oxymetholone, stanozolol, danazol, pharmaceutically acceptable esters and salts thereof, and combinations of any of the foregoing.

8. The method of Claim 5, further comprising administering a progestin in a daily dose.

9. A method of treating hormonal deficiencies in a woman undergoing estrogen replacement therapy comprising cyclically administering to said woman an estrogenic compound, and continuously and uninterruptedly administering to said woman a non-aromatizing androgenic compound.

10. The method of Claim 9, wherein the estrogenic compound is selected from the group consisting of estrone, 17 $\alpha$ -estradiol, 17 $\beta$ -estradiol, equilin, 17 $\alpha$ -dihydroequilin, 17 $\beta$ -dihydroequilin, equilenin, 17 $\alpha$ -dihydroequilenin, 17 $\beta$ -dihydroequilenin,  $\Delta^{8,9}$ -dehydroestrone, 17 $\alpha$ - $\Delta^{8,9}$ -dehydroestradiol, 17 $\beta$ - $\Delta^{8,9}$ -dehydroestradiol, ethinyl estradiol, estradiol valerate, 6-OH equilenin, 6-OH 17 $\alpha$ -dihydroequilenin, 6-OH 17 $\beta$ -dihydroequilenin, and mixtures, conjugates and salts thereof.

11. The method of Claim 9, wherein the non-aromatizing androgenic compound is selected from the group consisting of oxandrolone, oxymetholone, stanozolol, danazol, pharmaceutically acceptable esters and salts thereof, and combinations of any of the foregoing.

12. The method of Claim 9, further comprising administering a progestin in a daily dose.

13. A method of treating hormonal deficiencies in a woman undergoing estrogen replacement therapy comprising continuously and uninterruptedly administering daily dosages of a therapeutically effective amount of an estrogenic compound equivalent to estradiol dosages of about 0.1 to 3 mg, and continuously and uninterruptedly administering to said woman a

therapeutically effective amount of a non-aromatizing androgenic compound equivalent to oral dosages of about 0.1 to 10 mg.

14. The method of Claim 13, wherein the estrogenic compound is selected from the group consisting of estrone, 17 $\alpha$ -estradiol, 17 $\beta$ -estradiol, equilin, 17 $\alpha$ -dihydroequilin, 17 $\beta$ -dihydroequilin, equilenin, 17 $\alpha$ -dihydroequilenin, 17 $\beta$ -dihydroequilenin,  $\Delta^{8,9}$ -dehydroestrone, 17 $\alpha$ - $\Delta^{8,9}$ -dehydroestradiol, 17 $\beta$ - $\Delta^{8,9}$ -dehydroestradiol, ethinyl estradiol, estradiol valerate, 6-OH equilenin, 6-OH 17 $\alpha$ -dihydroequilenin, 6-OH 17 $\beta$ -dihydroequilenin, and mixtures, conjugates and salts thereof.

15. The method of Claim 13, wherein the non-aromatizing androgenic compound is selected from the group consisting of oxandrolone, oxymetholone, stanozolol, danazol, pharmaceutically acceptable esters and salts thereof, and combinations of any of the foregoing.

16. The method of Claim 13, further comprising administering a progestin in a daily dose.

17. A method of treating hormonal deficiencies in a woman undergoing estrogen replacement therapy comprising continuously and uninterruptedly administering to said woman an estrogenic compound, and continuously and uninterruptedly cyclically administering to said woman a non-aromatizing androgenic compound.

18. The method of Claim 17, wherein the estrogenic compound is selected from the group consisting of estrone, 17 $\alpha$ -estradiol, 17 $\beta$ -estradiol, equilin, 17 $\alpha$ -dihydroequilin, 17 $\beta$ -dihydroequilin, equilenin, 17 $\alpha$ -dihydroequilenin, 17 $\beta$ -dihydroequilenin,  $\Delta^{8,9}$ -dehydroestrone, 17 $\alpha$ - $\Delta^{8,9}$ -dehydroestradiol, 17 $\beta$ - $\Delta^{8,9}$ -dehydroestradiol, ethinyl estradiol, estradiol valerate, 6-OH equilenin, 6-OH 17 $\alpha$ -dihydroequilenin, 6-OH 17 $\beta$ -dihydroequilenin, and mixtures, conjugates and salts thereof.

19. The method of Claim 17, wherein the non-aromatizing androgenic compound is selected from the group consisting of oxandrolone, oxymetholone, stanozolol, danazol, pharmaceutically acceptable esters and salts thereof, and combinations of any of the foregoing.

20. The method of Claim 17, further comprising administering a progestin in a daily dose.

21. A method of treating hormonal deficiencies in a woman undergoing estrogen replacement therapy comprising continuously and uninterruptedly administering daily dosages of a therapeutically effective amount of an estrogenic compound equivalent to estradiol dosages of about 0.1 to 3 mg, and continuously and uninterruptedly cyclically administering to said woman a therapeutically effective amount of a non-aromatizing androgenic compound equivalent to oral dosages of about 0.1 to 10 mg.

22. The method of Claim 21, wherein the estrogenic compound is selected from the group consisting of estrone, 17 $\alpha$ -estradiol, 17 $\beta$ -estradiol, equilin, 17 $\alpha$ -dihydroequilin, 17 $\beta$ -dihydroequilin, equilenin, 17 $\alpha$ -dihydroequilenin, 17 $\beta$ -dihydroequilenin,  $\Delta^{8,9}$ -dehydroestrone, 17 $\alpha$ - $\Delta^{8,9}$ -dehydroestradiol, 17 $\beta$ - $\Delta^{8,9}$ -dehydroestradiol, ethinyl estradiol, estradiol valerate, 6-OH equilenin, 6-OH 17 $\alpha$ -dihydroequilenin, 6-OH 17 $\beta$ -dihydroequilenin, and mixtures, conjugates and salts thereof.

23. The method of Claim 21, wherein the non-aromatizing androgenic compound is selected from the group consisting of oxandrolone, oxymetholone, stanozolol, danazol, pharmaceutically acceptable esters and salts thereof, and combinations of any of the foregoing.

24. The method of claim 21, further comprising administering a progestin in a daily dose.

25. A pharmaceutical composition for the treatment of female hormonal deficiencies, said composition comprising:

a therapeutically effective amount of an estrogenic compound;

a therapeutically effective amount of a non-aromatizing androgenic compound; and

a pharmaceutically acceptable carrier.

26. The method of Claim 25, wherein the estrogenic compound is selected from the group consisting of estrone, 17 $\alpha$ -estradiol, 17 $\beta$ -estradiol, equilin, 17 $\alpha$ -dihydroequilin, 17 $\beta$ -dihydroequilin, equilenin, 17 $\alpha$ -dihydroequilenin, 17 $\beta$ -dihydroequilenin,  $\Delta^{8,9}$ -dehydroestrone, 17 $\alpha$ - $\Delta^{8,9}$ -dehydroestradiol, 17 $\beta$ - $\Delta^{8,9}$ -dehydroestradiol, ethinyl estradiol, estradiol valerate, 6-OH equilenin, 6-OH 17 $\alpha$ -dihydroequilenin, 6-OH 17 $\beta$ -dihydroequilenin, and mixtures, conjugates and salts thereof.

27. The pharmaceutical composition of Claim 25, wherein the non-aromatizing androgenic compound is selected from the group consisting of oxandrolone, oxymetholone, stanozolol, danazol, pharmaceutically acceptable esters and salts thereof, and combinations of any of the foregoing.

28. The pharmaceutical composition of Claim 25, further comprising a therapeutically effective amount of a progestin compound.